A Clinical Trial To Check The Efficacy Of Karkashchadadi Kwath In Medodushti (Dyslipidemia)

A Clinical Study Of Karkashchadadi Kwatha In Medodushti With Special Reference To Dyslipidemia

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/054923

Enrollment

Registered

2023-07-07

Start date

Unknown

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: i. Patients willing to sign the consent form. ii. Patients between the age group of 25-60 years of either sex. iii. Patients having underweight, normal weight, overweight, and class I obesity according to BMI iv. Diagnosed & confirmed cases of Medodushti (Dyslipidemia) & Medoroga on the basis of criteria given by NCEP-ATPIII. (Borderline High category).

Exclusion criteria

Exclusion criteria: a) Patient not fulfilling inclusion criteria. b) Patient not willing for clinical trial. c) Patient below 25yrs of age group and above 65yrs of age group. d) Patients having medical history of - Unstable angina, Myocardial Infarction, Heart failure or stroke. e) Uncontrolled Hypertension (Diastolic Blood Pressure > 100 mmHg). f) Uncontrolled Diabetes Mellitus. g) Impaired Renal Function (Creatinine > 2 mg/dl). h) ALT and AST >3 times of upper limit of normal. i) Patient on steroid therapy and oral contraceptive therapy. j) Pregnant and lactating patient.

Design outcomes

Primary

Measure	Time frame
The effect of drug will be analyzed on 1st 15th 30th 45th 60th day & after treatment by the means of change in subjective criteria & objective criteria (body weight, BMI, CBC, Lipid profile , SGOT, SGPT, Serum creatinine , FBS, Urine Routine & Microscopy,Timepoint: Approximate 60days per patient	—

Secondary

Measure	Time frame
1. To determine the effect of drug on clinical parameters & biochemical findings associated with Medodushti (Dyslipidemia). 2. To advise preventive measures to check the occurrence of disease in individual and masses. 3. To standardize the ayurvedic line of treatment, both drug and dose which may have effective role in management of patients of Medodushti (Dyslipidemia). 4. To explain the Medodushti (Dyslipidemia) critical review on the basis of classical text of ayurveda and with the help of modern literature. 5. To provide cheap, safe, and effective treatment from ayurveda to Dyslipidemic patients. 6. To rule out secondary causes that count for lipoprotein disorder. 7. To prevent the complication of Dyslipidemia like atherosclerosis, CAD, CVD & PVD. Timepoint: 2 year	—

Measure

Time frame

1. To determine the effect of drug on clinical parameters & biochemical findings associated with Medodushti (Dyslipidemia). 2. To advise preventive measures to check the occurrence of disease in individual and masses. 3. To standardize the ayurvedic line of treatment, both drug and dose which may have effective role in management of patients of Medodushti (Dyslipidemia). 4. To explain the Medodushti (Dyslipidemia) critical review on the basis of classical text of ayurveda and with the help of modern literature. 5. To provide cheap, safe, and effective treatment from ayurveda to Dyslipidemic patients. 6. To rule out secondary causes that count for lipoprotein disorder. 7. To prevent the complication of Dyslipidemia like atherosclerosis, CAD, CVD & PVD. Timepoint: 2 year

—

Countries

India

Contacts

Public ContactJYOTI

Shri Krishna Govt Ayurvedic College and Hospital

mehranilam@gmail.com9671368058

Outcome results